Literature DB >> 18789177

The burden of infection with cytomegalovirus in England and Wales: how many women are infected in pregnancy?

A J Vyse1, L M Hesketh, R G Pebody.   

Abstract

A serological survey was used to investigate the epidemiology of cytomegalovirus (CMV) infection in England and Wales. A total of 5237 sera representing the complete age range were used reflecting the general population. The sera were collected in 1991 and 2002, and screened for CMV-specific IgG by ELISA. Antibody prevalence increased with age from approximately 15% in those aged 1-4 years to approximately 80% in those aged > or = 65 years with no association with gender or region. Analysing by common birth cohort demonstrated that between 1991 and 2002 incidence was highest in children born 1985-1989 (1.62% per year, 95% CI 0.86-2.35), lower in older children and younger adults born 1950-1984 (0.75% per year, 95% CI 0.29-1.19) with little evidence of infection in older adults born pre-1950 (0% per year, 95% CI 0-0.64). Application to population and live-birth estimates for England and Wales suggested that between 1991 and 2002, 159 996 (95% CI 67922-278277) CMV infections occurred annually with an annual average of 2133 (95% CI 816-3435) infections affecting pregnant females.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18789177     DOI: 10.1017/S0950268808001258

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  16 in total

1.  Cytomegalovirus seropositivity is associated with herpes zoster.

Authors:  Benson Ogunjimi; Niel Hens; Richard Pebody; Hilde Jansens; Holly Seale; Mark Quinlivan; Heidi Theeten; Herman Goossens; Judy Breuer; Philippe Beutels
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Toxoplasma gondii seropositivity and co-infection with TORCH pathogens in high-risk patients from Qatar.

Authors:  Marawan A Abu-Madi; Jerzy M Behnke; Haydee A Dabritz
Journal:  Am J Trop Med Hyg       Date:  2010-04       Impact factor: 2.345

3.  Reply to letter Yates et al.

Authors:  Elizabeth M Hamilton; Naomi E Allen; Alexander J Mentzer; Thomas J Littlejohns
Journal:  J Infect Dis       Date:  2022-04-01       Impact factor: 5.226

4.  Shortness of breath in a patient with inflammatory bowel disease.

Authors:  Aoife Abbey; Amy C Elsmore
Journal:  BMJ Case Rep       Date:  2014-10-09

5.  Impaired NK Cell Responses to Pertussis and H1N1 Influenza Vaccine Antigens in Human Cytomegalovirus-Infected Individuals.

Authors:  Carolyn M Nielsen; Matthew J White; Christian Bottomley; Chiara Lusa; Ana Rodríguez-Galán; Scarlett E G Turner; Martin R Goodier; Eleanor M Riley
Journal:  J Immunol       Date:  2015-04-08       Impact factor: 5.422

6.  Major features of immunesenescence, including reduced thymic output, are ameliorated by high levels of physical activity in adulthood.

Authors:  Niharika Arora Duggal; Ross D Pollock; Norman R Lazarus; Stephen Harridge; Janet M Lord
Journal:  Aging Cell       Date:  2018-03-08       Impact factor: 9.304

7.  The convergent epidemiology of tuberculosis and human cytomegalovirus infection.

Authors:  Frank Cobelens; Nico Nagelkerke; Helen Fletcher
Journal:  F1000Res       Date:  2018-03-06

8.  Factors associated with cytomegalovirus serostatus in young people in England: a cross-sectional study.

Authors:  Joanne R Winter; Graham S Taylor; Olivia G Thomas; Charlotte Jackson; Joanna E A Lewis; Helen R Stagg
Journal:  BMC Infect Dis       Date:  2020-11-23       Impact factor: 3.090

9.  Cytomegalovirus infection does not impact on survival or time to first treatment in patients with chronic lymphocytic leukemia.

Authors:  Helen Marie Parry; Sarah Damery; Christopher Hudson; Matthew J Maurer; James R Cerhan; Annette Pachnio; Jusnara Begum; Susan L Slager; Christopher Fegan; Stephen Man; Christopher Pepper; Tait D Shanafelt; Guy Pratt; Paul A H Moss
Journal:  Am J Hematol       Date:  2016-06-01       Impact factor: 10.047

Review 10.  Cytomegalovirus and Epstein-Barr Virus Associations with Neurological Diseases and the Need for Vaccine Development.

Authors:  Peter A C Maple
Journal:  Vaccines (Basel)       Date:  2020-01-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.